EnteroMedics received $45.2 million in venture capital to develop clinical trials for its neuromodulation implant to spur weight loss in obese people, which the company aims to have ready in two to three years. The device is designed to block the vagus nerve, controlling the feeling of hunger and slowing digestion, which differs from the approach in Medtronic's and Cyberonics' devices, which work by stimulating the nerve to mimic the feeling of being full.

Full Story:

Related Summaries